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Abstract
Background: KRAS mutations in colorectal cancer primary tumors predict resistance to anti-Epidermal Growth Factor
Receptor (EGFR) monoclonal antibody therapy in patients with metastatic colorectal cancer, and thus represent a true
indicator of EGFR pathway activation status.
Methodology/Principal Findings: KRAS mutations were retrospectively studied using polymerase chain reactions and
subsequent sequencing of codons 12 and 13 (exon 2) in 110 patients with metastatic colorectal tumors. These studies were
performed using tissue samples from both the primary tumor and their related metastases (93 liver, 84%; 17 lung, 16%). All
patients received adjuvant 5-Fluorouracil-based polychemotherapy after resection of metastases. None received anti-EGFR
therapy. Mutations in KRAS were observed in 37 (34%) of primary tumors and in 40 (36%) of related metastases, yielding a
94% level of concordance (kappa index 0.86). Patients with primary tumors possessing KRAS mutations had a shorter
disease-free survival period after metastasis resection (12.0 vs 18.0 months; P=0.035) than those who did not. A higher
percentage of KRAS mutations was detected in primary tumors of patiens with lung metastases than in patients with liver
metastases (59% vs 32%; p=0.054). To further evaluate this finding we analyzed 120 additional patients with unresectable
metastatic colorectal cancer who previously had their primary tumors evaluated for KRAS mutational status for clinical
purposes. Separately, the analysis of these 120 patients showed a tendency towards a higher degree of KRAS mutations in
primary tumors of patients with lung metastases, although it did not reach statistical significance. Taken together the group
of 230 patients showed that KRAS was mutated significantly more often in the primary tumors of patients with lung
metastases (57% vs 35%; P=0.006).
Conclusions/Significance: Our results suggest a role for KRAS mutations in the propensity of primary colorectal tumors to
metastasize to the lung.
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Introduction
Colorectal cancer (CRC) is one of the most common
malignancies and one of the leading causes of cancer-related
death in developed countries [1]. Distant metastasis is the main
cause of death in CRC patients. Depending on the stage of the
primary tumor, liver metastases occur in 20% to 70% of patients,
and lung metastases in 10% to 20% of patients [2]. Surgical
resection remains the only potentially curative option for patients
with metastatic CRC. However, curative resection is possible in
less than 25% of patients with stage IV disease [3], and less than
5% of patients with unresectable metastatic CRC are alive after 5
years. Major efforts are being made to improve the prognosis for
patients with metastatic CRC, especially in the development of
new therapeutic strategies. The Epidermal Growth Factor
Receptor (EGFR) signalling pathway has become a key target
for therapeutic intervention because two monoclonal antibodies
directed against EGFR have become important tools in the
management of advanced disease: cetuximab and panitumumab
[4,5]. EGFR activates proliferative and antiapoptotic signalling
pathways, such as the phosphatidylinositol 39 kinase/Akt and Ras/
Raf/mitogen-activated protein kinase (MAPK) pathways [6].
Aberrant activation of the EGFR pathway in CRC could be
caused by either EGFR overexpression or mutational activation of
downstream elements of the EGFR pathway [7].
KRAS is a small GTP-binding protein that transduces signals
from activated cell surface receptors to the nucleus. Constitutive
KRAS activation by point mutations in codons 12 and 13 of exon 2
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overactivation [7,8]. The incidence of KRAS mutations in
colorectal tumors ranges from 35% to 45% [9], and KRAS
mutations seem to occur early in carcinogenesis [10]. Accordingly,
a high degree of concordance in KRAS mutational status between
primary tumors and their related liver metastases has been
reported [11,12]. Recent data have demonstrated an association
between KRAS mutational status in the primary tumor and
resistance to cetuximab and panitumumab in patients with
metastatic CRC [13,14]. However, the association between KRAS
mutational status and prognosis is controversial for patients with
metastatic CRC that have not been treated with anti-EGFR
antibodies, with some studies reporting a link between KRAS
mutations and poor prognosis [15] and some reporting no
association [12]. Interestingly, the largest multicentre study
conducted on the association between KRAS mutation and
prognosis, which included 3439 CRC patients, showed that the
presence of a glycine-to-valine mutation at codon 12 of KRAS
significantly decreased progression-free and overall survival rates
irrespective of the treatment received [16].
We sought to elucidate the correlation between KRAS
mutational status, clinicopathologic factors, prognosis, metastasis
pattern and concordance between the primary tumor and
matched metastases in patients with metastatic CRC.
Results
Patient Characteristics
We retrospectively analysed specimens from 110 primary
tumors and 110 corresponding metastatic sites for the presence
of KRAS mutations in codons 12 and 13. The most common
metastatic site was the liver, which was the metastatic site in 93
samples (84%). The lung was the metastatic site in the remaining
17 samples (16%). Metastases appeared synchronously with the
primary lesion in 57 cases and metachronously in 53 cases. The
primary tumor site was the colon in 79 patients and the rectum in
31 patients. The patient group included 32 women and 78 men.
Median age was 64 years (29-86). All cancers were adenocarci-
nomas and were graded according to WHO criteria (Table 1).
KRAS Mutations and Histopathological Parameters
Mutations in KRAS were detected in 37 (34%) primary tumors
and in 40 (36%) related metastatic lesions, with a 94% grade of
concordance between primary and metastatic samples (kappa
index 0.86). Discordance was observed in 7 patients. Five patients
had KRAS mutations in the metastases (four with liver metastases
and one with lung metastases) and wild type KRAS in the primary
tumor, whereas the two other patients had KRAS mutations only in
the primary tumor (1 with liver metastases and 1 with lung
metastases).
There was little variance between the mutation type present in
the primary tumor and its metastases: all but four patients had the
same mutation in both the primary and the metastatic samples.
The types of mutations are summarized in Table 2. There was no
relationship between the type of mutations and any clinicopath-
ological parameter.
No associations between KRAS mutations and histopathological
characteristics were observed (Table 3).
KRAS Mutations and Prognosis
Our results show lower rates of disease-free survival after
metastasis resection in patients whose tumors had a KRAS point
mutation in the primary tumor; median disease-free survival was
12 months in patients with KRAS mutations in their tumors and 18
months in those without KRAS mutations (p=0.035) (Figure 1).
The multivariate analysis showed that the most significant
independent predictor for disease-free survival was KRAS muta-
tional status (multivariate HR=2.068; 95% CI, 1.136–3.766,
P=0.018) (Table 4). No association was found between overall
survival and KRAS mutational status (figure 1).
KRAS Mutations and Metastatic Site
Mutated KRAS was detected in a higher proportion of primary
tumors of patiens with lung metastases than in those with liver
metastases (59% vs 32%, P=0.054). When stratified by origin of
Table 1. Patient characteristics.
Characteristic Value
Total number of primary tumors 110
Total number of metastatic samples 110
Liver 93
Lung 17
Age, median (range) 64 (29–86 yrs)
Gender (male/female) 78/32
Histological Grade
12
29 8
31 0
Primary tumor site (colon/rectum) 79/31
Primary stage (WHO classification)
I3
II 20
III 28
IV 59
Adjuvant treatment schedule
5-Fluorouracil/Leucovorin 36
Oxaliplatin/5-Fluorouracil/Leucovorin 46
Irinotecan/5-Fluorouracil/Leucovorin 28
Neoadjuvant treatment schedule
Radiotherapy (45 Gy)/5-Fluorouracil/Leucovorin 8
Radiotherapy (45 Gy)/Raltitrexed/Oxaliplatin 15
Radiotherapy (45 Gy)/Capecitabine/Oxaliplatin 8
Synchronous/Metachronous metastases 57/53
doi:10.1371/journal.pone.0008199.t001
Table 2. Codon distribution of specific KRAS mutations.
Mutations Primary tumors Liver metastases Lung metastases
Gly12Ala 2 2 1
Gly12Asp 16 12 4
Gly12Cys 2 2 0
Gly12Ser 0 0 1
Gly12Val 11 9 2
Gly13Asp 6 5 2
Total 37 30 10
doi:10.1371/journal.pone.0008199.t002
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primary tumors of patients with lung metastases, 7 were colonic in
origin (70%) whereas the other 3 originated in the rectum (30%).
Statistical analysis revealed that colonic primary tumors of patients
with lung metastases were significantly more likely to have KRAS
mutations than colonic primary tumors of patients with hepatic
metastases (P=0.046), whereas rectal primaries had a similar
frequency of KRAS mutations in patients with lung or liver
metastasis (Table 5). To further investigate the presence of KRAS
mutations as a predictor of lung metastasis, we also examined a
series of 120 patients with unresectable metastatic CRC. The
primary tumors of these patients had been analysed for the
presence of KRAS mutations by a central laboratory prior to
cetuximab administration. Of the 120 metastatic patients, 86 had
liver metastases and 34 had lung metastases. In addition, there was
a tendency towards a higher proportion of KRAS mutations in
primary tumors of patients with lung metastases than in those with
liver metastases, although it did not reach statistical significance
(56% vs 38%; P=0.1027). When we analysed the whole series of
230 patients, the frequency of KRAS mutations in the primary
tumors of patients with lung metastases was significantly higher as
compared with liver metastases (57% vs 35%; P=0.006). When
patients were stratified by primary tumor origin, only patients with
colonic primary tumor origin showed a significantly higher
frequency of KRAS mutations in primary tumors of patients with
lung metastases as compared with those with liver metastases (59%
vs 34%; P=0.019) (Table 6).
Discussion
The prognosis for patients with metastatic CRC has improved
since the introduction of novel therapeutic agents such as anti-
EGFR antibodies [17]. This therapeutic success highlights the
importance of counteracting the EGFR pathway to control
advanced disease. Aberrant activation of the EGFR pathway
sometimes occurs by mutational activation of KRAS. Recent
clinical trials have shown that the presence of activating mutations
in KRAS identifies patients who are non-responders to cetuximab
[13] or panitumumab [14]. In fact, based on these results,
mutational analysis of KRAS is now recommended by The US
Food and Drug Administration (FDA) prior to cetuximab or
panitumumab administration to patients with metastatic CRC.
Mutational analysis of KRAS is commonly performed on the
primary tumor because it is often the only available tissue.
Moreover, the value of performing this analysis on the primary
tumor is further supported by evidence that KRAS point mutations
occur early in CRC carcinogenesis [10]. However, recent data
have demonstrated an increased frequency of mutations in lymph
node metastases as compared with their related primary tumors
[18]. With this in mind, the potential need for rebiopsy and
analysis of KRAS in the metastases has been suggested [9]. Other
recent studies have reported a high degree of concordance in
KRAS mutational status between primary tumors and their related
liver metastases [11,12,19]. The results from our series of 110
patients are in complete agreement with these reports, both in the
frequency of KRAS mutations in primary tumors, which was 34%
in our study, and in the high degree of concordance between
primary tumors and their related metastases. All of these findings
confirm that analysis of KRAS mutational status in the primary
tumor is an adequate surrogate marker of KRAS mutational status
in metastases. Our study includes an analysis of both liver and lung
metastases. As far as we know, this is the first study to analyse
primary colorectal tumors and their related lung metastases and
correlated KRAS mutational status based on both clinicopatholog-
ical features and survival data. The liver and the lung are both
common sites of CRC metastases. Secondary to their respective
anatomical blood vessel distribution, lung metastases are more
common with rectal cancers and liver metastases are more
frequent with colon cancers. However, some colon cancer patients
experience lung metastases without evidence of previous liver
metastases. This unexplained anatomical pattern of metastasis,
observed with increasing frequency due to more accurate
diagnoses based on highly efficient CT scans [20], suggests a
peculiar biological mechanism of carcinogenesis or a special
susceptibility of the lung parenchyma to tumors in these patients.
Our results demonstrate a higher percentage of KRAS mutations in
primary tumors of patients with lung metastases as compared with
those with liver metastases (59% vs 32%). Moreover, when we
stratified our results based on the primary tumor site, only tumors
of colonic origin had a significantly higher frequency of KRAS
Table 3. Relationship between KRAS mutational status and
tumoral variables measured in primary tumors.
Mutated KRAS WT KRAS P value
Nu %N u %
Gender 0.376
Male 24 31% 54 69%
Female 13 41% 19 59%
Age 1.000
.60 24 33% 48 67%
,60 13 34% 25 66%
Tumor location 0.825
Rectum 11 36% 20 64%
Colon 26 33% 53 67%
Obstruction 0.616
Yes 6 27% 16 73%
No 31 35% 57 65%
Perforation 0.176
Yes 4 67% 2 33%
No 33 32% 71 68%
Primary tumor stage 0.970
I 1 33% 2 67%
II 6 30% 14 70%
III 9 32% 19 68%
IV 21 36% 38 64%
Metastasis presentation 0.546
Synchronous 21 37% 36 63%
Metachronous 16 30% 37 70%
Lymphatic invasion 0.095
Yes 9 53% 8 47%
No 28 30% 64 70%
Venous invasion 0.616
Yes 6 27% 16 73%
No 31 36% 56 64%
Perineural invasion 0.760
Yes 5 39% 8 61%
No 32 33% 64 67%
doi:10.1371/journal.pone.0008199.t003
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contrast, rectal primary tumors showed a similar frequency of
KRAS mutations in patients with lung metastases than in those with
liver metastases. To further analyze this finding we studied an
independent series of primary tumors from patients with
unresectable metastatic CRC and examined the relationship
between KRAS mutational status in the primary tumor and the
site of tumor metastasis. In these patients, KRAS mutational status
in the primary tumor was previously analysed for clinical purposes
prior to cetuximab administration. Statistical analysis of the whole
series (230 patients) revealed that KRAS is more frequently mutated
in the primary tumors of patients with lung metastases compared
with patients with liver metastases (57% vs 35%, P=0.006). When
the results are stratified according to the site of the primary tumor,
the analysis we performed including all 230 patients confirmed the
results we obtained with the smaller sample of 110 patients: that
the significantly increased frequency of KRAS mutations in primary
tumors in patients with lung metastases was restricted to those
primary tumors that originated in the colon. This finding suggests
that EGFR pathway activation may allow colonic tumor cells to
nest preferentially in the lung parenchyma avoiding an initial step
of liver metastasis. A previous study that evaluated KRAS status in
primary colorectal tumors and non-matched liver and lung
metastases showed concordant results with our study and revealed
a higher incidence of KRAS mutations in lung metastases than in
liver metastases (57% vs 50%) [21]. However, in that study, a
major difference in KRAS activation between the primary and
metastatic tumors could have been masked by the absence of
related primary and metastatic samples. This finding has clinical
importance because it may allow the identification of patients who
are more likely to develop lung metastases based on KRAS analysis
of the primary tumor. These patients should potentially receive a
more thorough clinical workup, including a thorax scan, which is
not always included in the standard clinical workup for CRC.
Our results also show that the presence of KRAS mutations is an
independent prognostic factor in the prediction of disease-free
survival (reaching statistical significance). Constitutive activation of
the Ras-Raf-MAP-kinase pathway is known that confers prolifer-
ative and disseminative advantage to tumor cells. However,
controversy exists regarding the prognostic role of KRAS
mutations in CRC. The biggest clinical trial designed to analyse
the prognostic value of KRAS status was the RASCAL study, which
showed that a glycine-to-valine mutation in codon 12 increased
the risk of recurrence and death by 30%, irrespective of the type of
therapy administered [16]. However, a recent study performed
Figure 1. Kaplan-Meier survival analysis. Curves for disease-free survival (A) and overall survival (B) according to KRAS status.
doi:10.1371/journal.pone.0008199.g001
Table 4. Multivariate disease-free survival analysis.
HR 95% CI P
Primary tumor KRAS status 2,068 1,136–3,766 0,018
Primary tumor stage 1,165 0,868–1,563 0,310
Metastases size 0,999 0,899–1,109 0,981
Total number of metastases 1,018 0,876–1,184 0,813
Neoadjuvant treatment 1,457 0,770–2,755 0,247
Metastasis site 0,582 0,274–1,237 0,159
Abbreviations: HR: Hazard Ratio. CI: Confidence Interval.
doi:10.1371/journal.pone.0008199.t004
Table 5. KRAS mutational status in the primary tumor
according to the metastatic site (series of 110 patients).
Metastatic
site WT Mutated Total P
KRAS (colon) 0,046
liver 47 (69%) 21 (31%) 68
lung 4 (36%) 7 (64%) 11
KRAS (rectum) 0,653
liver 16 (64%) 9 (36%) 25
lung 3 (50%) 3 (50%) 6
doi:10.1371/journal.pone.0008199.t005
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did not demonstrate any influence of KRAS mutations on survival
[12]. Thus, the prognostic value of KRAS mutational status
remains controversial. Our results are in agreement with the
RASCAL study and suggest a poorer prognosis for patients with
KRAS-mutated primary tumors, with a significant association
between KRAS mutational status and a shorter disease-free
survival. By contrast, no association was found between KRAS
status and overall survival. This can be explained by the
administration of chemotherapy after relapse. The multivariate
analysis shows that the presence of KRAS mutations is an
independent prognostic factor in the prediction of disease-free
survival (reaching statistical significance), thus highlighting the
relevance of KRAS mutational status in the present series of
patients. Regarding a potential influence of the mutation type on
prognosis, our results, in contrast to the RASCAL study, show no
differences with respect to mutation type. Of course, the potential
value of KRAS mutations as a prognostic factor shown in this study
must be taken cautiously, due to the limited and particular series of
patients evaluated.
In summary, our findings suggest that KRAS-mutated primary
CRC tumors tend to metastasize more frequently to the lung and
are associated with a higher rate of relapse after resection of the
metastases. This finding could be of clinical interest with regard to
the follow-up of patients with KRAS-mutated primary CRC
tumors, and thus merits further investigation.
Methods
Ethics Statement
The Ethical Committee of the La Paz University Hospital in
Madrid, Spain, approved the current study. All patients were
informed and consented in writing.
Eligible Patients
One hundred and ten patients with metastatic CRC with
available primary tumor and paired metastatic specimens were
selected from a database of patients from La Paz University
Hospital in Madrid. This study was approved by the hospital’s
ethics committee. The patients were diagnosed with metastatic
CRC between 1997 and 2007. Of the 326 cases of metastatic
CRC diagnosed during this time period, study inclusion was
limited to those with curative metastasis resection, available tissue
specimens (both from the primary tumor and related metastases),
available follow-up data after metastasis removal, and successful
KRAS mutational status analysis. The median follow-up after
surgery was 10 months (range: 0–144 months). All tumors were
histologically confirmed to be colorectal adenocarcinomas. In
addition, pathology reports included information on the tumor
site, tumor size, pathological stage, tumor grade (based on the
degree of histological differentiation), presence or absence of
lymph node metastasis, tumor growth pattern (infiltrative or
expansive), presence or absence of vascular and lymphatic
invasion, and presence or absence of tumor lymphocytic infiltrates.
The primary stage has been classified into 4 stages according to
WHO criteria. The number and size of metastases were
determined by diagnostic imaging, either with abdominal and
pelvic computed tomography or with magnetic resonance
imaging. Metastasis resection was performed when there was no
evidence of extra-hepatic disease, ensuring enough functioning
residual liver after resection (approximately 25%–30% of normal
liver volume) to provide hepatic function postoperatively, adjusted
based on existing liver disease such as cirrhosis or hepatitis.
Metastatic samples were obtained from either the liver or the lung.
These metastatic samples were obtained from either synchronous
or metachronous lesions. Patients received one of three different
chemotherapy regimens after metastasis resection (described in
Table 1).
After the discovery of the discordance between KRAS mutations
in liver and lung metastases, an additional series of 128 metastatic
CRC patients (86 with liver metastasis, 34 with lung metastasis,
and 8 with other types of mutations (these last 8 patients were not
included in the statistical analysis) from La Paz Hospital were
prospectively collected between 2007 and 2009, to validate the
hypothesis of a higher rate of KRAS mutations in patients with lung
metastases. These patients had unresectable metastatic disease.
KRAS status in the primary tumor was determined for clinical
purposes prior to cetuximab administration. The only clinico-
pathological data collected for these patients was the site of the
primary tumor (colon vs rectum). KRAS analysis was performed
using the TheraScreen K-RAS mutation test kit (DXS Diagnostic
Innovations) by an independent central laboratory in Madrid,
following the manufacturer’s instructions.
DNA Extraction
Paraffin-embedded primary tumor specimens (n=110) and
metastatic tumor specimens (n=110) containing at least 70%
tumor cells were selected for each patient. Tissue blocks were
macro-dissected using a safety blade when samples were less than
70% enriched with tumoral cells. Metastatic tumors were located
in the liver (n=93) and the lung (n=17). DNA was isolated from
15 7-mm paraffin sections. Tissue sections were deparaffinated
with xilol and rehydrated with downgraded alcohols. Tissues were
digested with Proteinase K, and DNA was isolated using a
MasterPure DNA Kit (Epicentre, Biotechnologies). In each
instance, negative controls were amplified by PCR and included
in the experiment.
KRAS Mutation Analysis
A polymerase-chain reaction (PCR) was performed to amplify
139 bp of exon 2 in KRAS using specific primers (kindly donated
by Dr. Laurent-Puig’s laboratory) and under PCR conditions
described previously [15]. PCR primer sequences/conditions are
available upon request. The efficiency and quality of the
amplification PCR were confirmed by running the PCR products
on a 2% agarose gel. A negative control containing all the
components of the PCR except the template was included in each
PCR reaction. DNA Amplified products were purified using a
QuickStep TM 2 96–Well PCR Purification Kit (Edge BioSys-
tems, Gaithersburg, MD), according to the manufacturer’s
instructions. Amplification products were bidirectionally se-
quenced via the fluorescence dye terminator method in a multi-
Table 6. KRAS mutational status in the primary tumor
according to metastatic site (whole series of 230 patients).
Metastatic
site WT Mutated Total P
KRAS (colon) 0,019
liver 91 (66%) 46 (34%) 137
lung 12 (41%) 17 (59%) 29
KRAS (rectum) 0,304
liver 25 (60%) 17 (40%) 42
lung 10 (45%) 12 (55%) 22
doi:10.1371/journal.pone.0008199.t006
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Madrid (Madrid, Spain). Presence of mutation was accepted when
it chromatographic peak height was 25% or higher the peak of the
wild type reference.
Statistical Analyses
Fisher’s exact test was used to examine the association between
KRAS mutational status and various clinicopathological features.
Concordance between the primary tumor and related metastases
was analysed using the kappa index, and discordance was analysed
using the McNemar test of symmetry. Disease-free survival and
overall survival analyses were calculated according to the Kaplan
Meier method, and survival curves were compared using the log-
rank test. Disease-free survival was defined as the time from
surgical resection of the metastases until the time of documented
tumor progression or death. A Cox proportional hazards
multivariate regression analysis was performed. P,0.05 was
considered significant. Statistical analyses were performed using
SPSS version 12.0 (Chicago, IL, USA).
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